The industry of high potency APIs is growing due to the investments made by the pharma and biotech firms in oncology, personalized therapy, specialty drug products, and precision therapies. High potency active pharmaceutical ingredients are utilized in the manufacture of drugs with low concentration to achieve their therapeutic effects. Such drugs are particularly significant in cancer treatments and other highly targeted drugs. Increased research activities, growing demand for complex chemicals, and outsourcing of production process to specialized partners are factors driving the development of containment technology, formulation science, automation, and HPAPI manufacturing facilities.
According to the research from SNS Insider, the value of the High Potency APIs (HPAPI) Market in 2025 reached USD 29.65 billion and is expected to grow to USD 69.81 billion in 2035 at a CAGR of 8.94%. The main reason behind such growth in the market is growing demand for cancer treatments and increased research in oncology.
Gain Actionable Intelligence on the High Potency APIs (HPAPI) Market – Request a Free Sample Report
Targeted Therapies, Oncology, and Outsourcing Are Driving Global Demand
The need for HPAPIs will be driven by the move towards drugs that are targeted at certain biological targets. Cancer is still the largest therapeutic segment, comprising about 52.46% of market share in 2025, due to ongoing developments of cytotoxic agents, precision medicine, immuno-oncology agents and combination drugs. The market share of cytotoxic APIs was about 41.28%. This is due to the fact that cytotoxic APIs have been in use for many years in cancer research and chemotherapy. On the other hand, immunomodulators are projected to have high growth of 10.67% CAGR due to growing immune-oncology and autoimmune pipeline. The applications of infectious disease will record a strong market growth due to development of anti-infective APIs.
Contract manufacturing also forms a huge area for growth. Drug companies are increasingly outsourcing HPAPIs due to the fact that such substances need containment, qualified personnel, validation of processes and manufacturing facilities. Contract manufacturing is expected to have a 10.22% CAGR growth driven by investments into capacity expansion of CDMOs. North America accounted for approximately 39.74% of the global market because of its strong oncology pipeline, biotechnology activities, advanced manufacturing and large network of CDMOs. The region with the highest growth rate is Asia Pacific which will grow at approximately 11.48% CAGR due to growing pharmaceutical manufacturing and containment manufacturing in China, India, Japan, South Korea, and Australia. Europe continues to be an important manufacturing base as well.
Companies Advancing the Global HPAPI Industry
Pfizer Inc.
Pfizer is one of the leading biopharmaceutical companies that has strong presence in oncology, specialty medicines, vaccines, and targeted medicines. The involvement of the company in the world of HPAPI is backed by heavy investments in R&D, manufacturing capacity and development projects of complex and high-potency products. Pfizer announced positive top-line results from its Phase 3 LP.8.1-adapted COMIRNATY program in March 2025. Overall, the investment in targeted medicines, biologics, containment solutions and specialty manufacturing capabilities of Pfizer helps in its involvement in HPAPIs.
Novartis AG
Novartis continues to have a significant presence in innovation-based drugs such as oncology drugs, rare diseases drugs, and precision medicines which depend on specialized high-potency substances in the process of manufacture. Novartis integrates heavy research and development spending with biopharmaceutical manufacturing and pharmaceutical manufacturing capabilities. Novartis obtained regulatory approvals in April 2025 for the following drugs: Pluvicto and Vanrafia. This enhances its portfolio in the area of precision medicines for oncology and nephrology.
Merck & Co., Inc.
Merck is a key player in the field of oncology, biologics, and precision medicines through robust research activities and state-of-the-art drug manufacturing process capabilities. The high impact of its pharmaceutical product portfolio keeps generating the demand for active ingredients, containment solutions, and the process of manufacturing of such products. On May 2025, Merck launched a subcutaneous formulation of Keytruda in the United States to make it more convenient for patients. Development of oncology and biologic drugs is making Merck a key player in the high potency product market.
Global HPAPI Outlook Through 2035
The global HPAPI market would witness continued growth until 2035 due to the progress made in the precision oncology pipelines, immunotherapies, biologics, oligonucleotides, and many other precision therapies in their clinical phases and commercialization processes.Growth in the partnerships between manufacturers and contract development and manufacturing organizations (CDMOs) continues to be critical since pharma and biotech firms aim at gaining access to advanced facilities without developing their high-containment capabilities. Nevertheless, regulatory requirements, complicated handling, high manufacturing costs, special labor force requirements, and significant infrastructure investments are still critical barriers.
High Potency APIs (HPAPI) Market is expected to reach USD 69.81 billion by 2035, and the producers and CDMOs that will possess advanced containment capabilities, flexible capacity, regulatory compliance, formulation know-how, automation, and scalable manufacturing processes are expected to benefit from the increase in the proportion of precision drugs under development.
